ArticleJournal of cannabis research2026
Longitudinal analysis of symptoms and healthcare utilization among daily cannabis-using persons living with HIV: impact of co-occurring cocaine use.
Article in Journal of cannabis research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01536899 (Behavioral Economic Analysis of Medical Marijuana Use in HIV+ Patients Prospective Cohort Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Behavioral Economic Analysis of Medical Marijuana Use in HIV+ Patients Prospective Cohort Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCannabis use is common among persons living with human immunodeficiency virus (HIV, PLWH) and has been associated with disrupted sleep, psychiatric symptoms, and increased healthcare utilization. However, the influence of concurrent cocaine and cannabis use on symptom trajectories and healthcare engagement remains unclear.
methodsOne hundred nineteen PLWH who reported daily cannabis use were assessed longitudinally: baseline, 3-month, and 6-month follow-up. Participants were stratified into concurrent cocaine users vs. non-users based on urine drug screen results (Coc + n = 34 vs. Coc- n = 85). Assessments included substance-use characteristics, viral load, healthcare utilization (HIV-specific vs. non-specific medical visits), HIV-related symptoms (poor sleep, fatigue, pain, poor appetite), and psychiatric symptoms (depression, anxiety).
resultsFrom baseline to 6-month follow-up, HIV clinic visit frequency declined 46.7% (p = 0.002), which was predicted by less-frequent baseline cannabis use (p = 0.03). Poor sleep, fatigue, and poor appetite reliably correlated with psychiatric symptom severity (rs = 0.23-0.57), whereas pain severity was most closely linked to non-HIV-specific healthcare utilization (rs = 0.23-0.36). Cocaine co-use was associated with greater non-HIV-specific healthcare utilization, worse sleep, and less-frequent cannabis use (ps < 0.05).
conclusionsAmong daily cannabis-using PLWH, less-frequent cannabis use at study baseline predicted a 47% decline in HIV clinic visits suggesting that frequent cannabis use (or associated factors) may perpetuate continued HIV healthcare utilization. Cocaine co-use was associated with greater healthcare utilization, worse sleep quality, and less-frequent cannabis use, but did modulate self-reported depression or anxiety symptoms. In sum, our findings show a complex interplay between longitudinal patterns of cannabis use, somatic and psychiatric symptom severity, and healthcare utilization among PLWH.
trial registrationThis study was registered at ClinicalTrials.gov (NCT01536899).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.